PL370430A1 - Sposób podawania peptydu tymozyny alfa 1 - Google Patents

Sposób podawania peptydu tymozyny alfa 1

Info

Publication number: PL370430A1
Authority: PL; Poland
Prior art keywords: peptide; thymosin alpha; administering; patient; immune
Prior art date: 2001-11-01

Application number

PL02370430A

Other languages

English (en)

Other versions

PL208388B1 (pl

Inventor

Alfred R. Rudolph

Cynthia W. Tuthill

Original Assignee

Sciclone Pharmaceulticals, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-11-01

Filing date

2002-11-01

Publication date

2005-05-30

2002-11-01 Application filed by Sciclone Pharmaceulticals, Inc. filed Critical Sciclone Pharmaceulticals, Inc.

2005-05-30 Publication of PL370430A1 publication Critical patent/PL370430A1/pl

2011-04-29 Publication of PL208388B1 publication Critical patent/PL208388B1/pl

Links

108010078233 Thymalfasin Proteins 0.000 title abstract 4
238000000034 method Methods 0.000 title abstract 2
102400000800 Thymosin alpha-1 Human genes 0.000 abstract 2
NZVYCXVTEHPMHE-ZSUJOUNUSA-N thymalfasin Chemical compound CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NZVYCXVTEHPMHE-ZSUJOUNUSA-N 0.000 abstract 2
229960004231 thymalfasin Drugs 0.000 abstract 2
238000001802 infusion Methods 0.000 abstract 1
108090000765 processed proteins & peptides Proteins 0.000 abstract 1
230000004936 stimulating effect Effects 0.000 abstract 1
230000000638 stimulation Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2292—Thymosin; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Virology (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Molecular Biology (AREA)
Endocrinology (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Biotechnology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)

PL370430A 2001-11-01 2002-11-01 Zastosowanie peptydu tymozyny α 1 (TA1) PL208388B1 (pl)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US33087401P	2001-11-01	2001-11-01

Publications (2)

Publication Number	Publication Date
PL370430A1 true PL370430A1 (pl)	2005-05-30
PL208388B1 PL208388B1 (pl)	2011-04-29

Family

ID=23291672

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL370430A PL208388B1 (pl)	2001-11-01	2002-11-01	Zastosowanie peptydu tymozyny α 1 (TA1)

Country Status (19)

Country	Link
US (2)	US20050049191A1 (pl)
EP (1)	EP1450850B1 (pl)
JP (1)	JP2005511563A (pl)
KR (1)	KR20050042229A (pl)
CN (1)	CN1582163A (pl)
AT (1)	ATE481980T1 (pl)
AU (1)	AU2002363248B2 (pl)
BR (1)	BR0213823A (pl)
CA (1)	CA2464307A1 (pl)
DE (1)	DE60237784D1 (pl)
EA (1)	EA008536B1 (pl)
ES (1)	ES2353379T3 (pl)
IL (2)	IL161665A0 (pl)
MX (1)	MXPA04004187A (pl)
NO (1)	NO327101B1 (pl)
NZ (1)	NZ532763A (pl)
PL (1)	PL208388B1 (pl)
UA (1)	UA80957C2 (pl)
WO (1)	WO2003037366A1 (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN100501400C (zh) *	2002-11-25	2009-06-17	希克龙制药公司	使用α胸腺素防护辐射损伤的方法
BRPI0408892A (pt) *	2003-03-28	2006-04-11	Sciclone Pharmaceuticals Inc	uso de timosina alfa 1 para tratar as infecções por arpergillus
US8017129B2 (en)	2006-06-15	2011-09-13	SciClone Pharmaceuticals International Ltd	Use of thymosin alpha 1 for preparing a medicament for the treatment of stage IV malignant melanoma
US20080300166A1 (en) *	2007-06-01	2008-12-04	Sciclone Pharmaceuticals, Inc.	Treatment of Melanoma with Alpha Thymosin Peptides
JP2011506467A (ja) *	2007-12-14	2011-03-03	サイクローン・ファーマシューティカルズ・インコーポレイテッド	抗悪性腫瘍性熱ショックアポトーシス活性化因子（ｈｓａａ）と組み合わせられたアルファチモシンペプチドによる黒色腫の処置の方法
EP2427213B1 (en)	2009-05-08	2015-04-01	Sciclone Pharmaceuticals, Inc.	Alpha thymosin peptides as vaccine enhancers
US20150031617A1 (en) *	2012-03-08	2015-01-29	Sciclone Pharmaceuticals, Inc.	Use of thymosin alpha for treatment of purulent rhinosinusitis
US20130296223A1 (en)	2012-03-30	2013-11-07	Sciclone Pharmaceuticals, Inc.	Use of thymosin alpha for the treatment of sepsis
EP3943101A1 (en) *	2014-10-21	2022-01-26	SciClone Pharmaceuticals International Ltd.	Treatment of cancer with immune stimulator alpha thymosin peptide
BR112017016205A2 (pt) *	2015-02-09	2018-03-27	Romani Luigina	thymosin alpha 1 para uso no tratamento de fibrose cística

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4447233A (en) *	1981-04-10	1984-05-08	Parker-Hannifin Corporation	Medication infusion pump
US4444757A (en) *	1981-11-16	1984-04-24	Research Corporation	Use of thymosin as an anti-diabetes and anti-hypertensive disease agent
TW224053B (pl) *	1991-09-13	1994-05-21	Paul B Chretien
US5468729A (en) *	1993-10-26	1995-11-21	Alpha 1 Biomedicals	Method for treatment of autoimmune hepatitis
US5760000A (en) *	1994-05-13	1998-06-02	University Technologies International,Inc.	Inhibition of liver cancer by the use of GnRH and GnRH analogs
US5888980A (en) *	1994-06-30	1999-03-30	Bio-Logic Research And Development Corporation	Compositions for enhancing immune function
US5632983A (en) *	1994-11-17	1997-05-27	University Of South Florida	Method for treating secondary immunodeficiency
US5849596A (en) *	1996-07-08	1998-12-15	Food Industry Research And Development Institute	Process for determining the smoke content of edible oil
AU7788701A (en) *	2000-07-14	2002-01-30	Transform Pharmaceuticals Inc	System and method for optimizing tissue barrier transfer of compounds
JP2004532809A (ja) *	2000-11-02	2004-10-28	リサーチファウンデーションオブシティユニバーシティオブニューヨーク	ホスホジエステラーゼ４型を阻害することによって、神経系の再生および修復を刺激するための方法

2002
- 2002-01-11 UA UA20040504064A patent/UA80957C2/uk unknown
- 2002-11-01 DE DE60237784T patent/DE60237784D1/de not_active Expired - Lifetime
- 2002-11-01 KR KR1020047006674A patent/KR20050042229A/ko not_active Ceased
- 2002-11-01 IL IL16166502A patent/IL161665A0/xx active IP Right Grant
- 2002-11-01 MX MXPA04004187A patent/MXPA04004187A/es active IP Right Grant
- 2002-11-01 WO PCT/US2002/035093 patent/WO2003037366A1/en not_active Ceased
- 2002-11-01 EA EA200400591A patent/EA008536B1/ru not_active IP Right Cessation
- 2002-11-01 US US10/493,848 patent/US20050049191A1/en not_active Abandoned
- 2002-11-01 CN CNA02821871XA patent/CN1582163A/zh active Pending
- 2002-11-01 EP EP02802520A patent/EP1450850B1/en not_active Expired - Lifetime
- 2002-11-01 AT AT02802520T patent/ATE481980T1/de not_active IP Right Cessation
- 2002-11-01 ES ES02802520T patent/ES2353379T3/es not_active Expired - Lifetime
- 2002-11-01 PL PL370430A patent/PL208388B1/pl not_active IP Right Cessation
- 2002-11-01 JP JP2003539708A patent/JP2005511563A/ja active Pending
- 2002-11-01 BR BR0213823-9A patent/BR0213823A/pt not_active IP Right Cessation
- 2002-11-01 CA CA002464307A patent/CA2464307A1/en not_active Abandoned
- 2002-11-01 AU AU2002363248A patent/AU2002363248B2/en not_active Ceased
- 2002-11-01 NZ NZ532763A patent/NZ532763A/en not_active IP Right Cessation
2004
- 2004-04-29 IL IL161665A patent/IL161665A/en not_active IP Right Cessation
- 2004-05-21 NO NO20042100A patent/NO327101B1/no not_active IP Right Cessation
2010
- 2010-05-07 US US12/775,986 patent/US20100221274A1/en not_active Abandoned

Also Published As

Publication number	Publication date
UA80957C2 (en)	2007-11-26
BR0213823A (pt)	2004-08-31
NO20042100L (no)	2004-05-21
CA2464307A1 (en)	2003-05-08
WO2003037366A1 (en)	2003-05-08
US20050049191A1 (en)	2005-03-03
IL161665A (en)	2011-03-31
NO20042100D0 (no)	2004-05-21
CN1582163A (zh)	2005-02-16
EA200400591A1 (ru)	2004-10-28
EA008536B1 (ru)	2007-06-29
ES2353379T3 (es)	2011-03-01
KR20050042229A (ko)	2005-05-06
US20100221274A1 (en)	2010-09-02
EP1450850B1 (en)	2010-09-22
EP1450850A4 (en)	2005-11-30
ATE481980T1 (de)	2010-10-15
PL208388B1 (pl)	2011-04-29
DE60237784D1 (de)	2010-11-04
NZ532763A (en)	2008-01-31
NO327101B1 (no)	2009-04-20
MXPA04004187A (es)	2004-07-08
EP1450850A1 (en)	2004-09-01
AU2002363248B2 (en)	2007-11-22
JP2005511563A (ja)	2005-04-28
IL161665A0 (en)	2004-09-27

Legal Events

Date	Code	Title	Description
2011-11-30	RECP	Rectifications of patent specification
2013-12-31	LAPS	Decisions on the lapse of the protection rights	Effective date: 20121101

Publication	Publication Date	Title
AU2000277238A1 (en)	2001-10-15	Non-mammalian gnrh analogs and uses thereof in tumor cell growth regulation and cancer therapy
WO2001060381B1 (en)	2001-11-01	Nucleoside analogs with carboxamidine-modified bicyclic base
CA2129541A1 (en)	1994-07-07	Method of Promoting Nitrogen Retention in Humans
DK0490991T3 (da)	1993-11-29	Doseringsform til oral administration af hypoglykæmisk glipizid
MXPA05006572A (es)	2005-12-14	Composiciones y metodos para la administracion mejorada por via mucosa de peptidos fijadores al receptor de y2 y metodos para tratar y prevenir la obesidad.
WO1987004076A1 (en)	1987-07-16	Low dosage of interferon to enhance vaccine efficiency
IL208184A0 (en)	2010-12-30	Glp-1, and methods for treating diabetes
DE60327843D1 (de)	2009-07-16	Arzneimittelformulierungen mit verzögerter freisetzung mit einem trägerpeptid
BG106171A (en)	2002-06-28	Compositions and uses of et743 for treating cancer
MY103746A (en)	1993-09-30	Improvements in or relating to somatostatins
IL161665A0 (en)	2004-09-27	Method of administering a thymosin alpha 1 peptide
EA200400548A1 (ru)	2005-06-30	Лечение тяжёлой пневмонии путём введения ингибитора пути тканевого фактора (tfpi)
IL161670A0 (en)	2004-09-27	Thymosin alpha 1 peptide/polymer conjugates
JP2002530353A5 (pl)	2006-12-14
DK1173476T3 (da)	2007-02-19	Funktionelle sojabönneproteiner
AR023185A1 (es)	2002-09-04	Tratamiento de cancer mejorado con temozolomida
MY106603A (en)	1995-06-30	Treatment of genital warts with a combination of liquid nitrogen and recombinant dna human alpha interferon
TW200517119A (en)	2005-06-01	Method of treatment using interferon-tau
ATE205397T1 (de)	2001-09-15	Natürliches menschliches alpha interferon enthaltende pharmazeutische zusammensetzungen
WO2003072019A3 (en)	2003-12-18	Sequential therapy comprising a 20(s)-camptothecin compound and a pyrimidine base analog
JPS6447715A (en)	1989-02-22	Improver for ovulation inductive pregnant genital physiological dysfunction
MD197G2 (ro)	1996-10-31	Preparat şi procedeu de tratare a hipogalactiei
MD1780F1 (en)	2001-11-30	Method of treatment of patients with hepatic cirrhosis
AU4918900A (en)	2000-11-14	Interferon-beta use in the treatment of ewing's family of tumors
MD1469G2 (ro)	2001-01-31	Metodă de tratament al şocului combustional